NCT05937867View on ClinicalTrials.gov

A Phase II Study of HS-10353 in Participants With Postpartum Depression

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

October 31, 2025

Conditions
Postpartum Depression
Interventions
DRUG

HS-10353 Capsules 30 mg, Oral, QN for 14 days

HS-10353 Capsules 30 mg

DRUG

HS-10353 Capsules 50 mg, Oral, QN for 14 days

HS-10353 Capsules 50 mg

DRUG

HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.

Placebo

DRUG

HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days

Placebo

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY